FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782372411> ?p ?o ?g. }

• W2782372411 endingPage "2843" @default.
• W2782372411 startingPage "2843" @default.
• W2782372411 abstract "Abstract Abstract Objective: For more than two decades,CHOP (and later R-CHOP) has been the standard frontline treatment for diffuse large b-cell lymphoma (DLBCL). However, anthracycline-based chemotherapy regimens increase risk of cardiotoxicity with congestive heart failure (HF) being the best documented cardiovascular complication of anthracycline use. However, cardiotoxicity has also been associated with other chemotherapeutic drugs. In this nationwide cohort study, we compared the incidence of development of HF in patients with DLBCL or follicular lymphoma (FL) treated with or without anthracyclines. Methods: DLBCL and FL patients > 16 years both receiving anthracycline in the form of R-CHOP/CHOEP or non-anthracycline chemotherapy regiments were identified in the Danish National Lymphoma Registry (LYFO) from 2000-2012. Anthracycline exposed patients were required to receive ≥3 cycles of R-CHOP or R-CHOEP upfront. The non-anthracycline exposed patients consisted of patients receiving non-anthracycline containing chemotherapy (such as CVP, CEOP and Bendamustine). Exclusion criteria were i) treatment with chemo therapy regimens more intensive than R-CHOP/CHOEP, ii) up-front high dose autologous stem cell transplantation and iii) the following heart comorbidities prior to the beginning of the study: HF (ICD-10 code: “I50”), Ischemic Heart Disease (ICD-10 code: “I20-I25”), Arrhythmic Heart Disease (ICD-10 code: “I48-I49”) and Cardiomyopathy (ICD-10 code: “I42”). Information on heart comorbidities in our study population were retrieved from the Danish National Patient Registry. Patient follow-up started from 30 days after ended chemotherapy to minimize confounding by early HF on the planned number of R-CHOP treatments. Follow-up ended when HF occurred, on the day of emigration from Denmark, day of death or the end of the study on 31th. December 2014, whichever came first. Univariate and multivariable cox regression analyses were performed to assess the association between cumulative anthracycline treatments and HF (adjusted analysis included gender, age, Ann Arbor stadium, radiotherapy, comorbidities and type of lymphoma). Cumulative R-CHOP treatments were stratified into groups of “3-5”, “6” and “>6” treatments. Cumulative incidence curves were computed to illustrate risk of HF over time according to number of treatments. Results: The study included 2,696 patients; 2,007 received anthracycline and 689 received non-anthracycline containing chemotherapy. In total, 1979 patients were diagnosed with DLBCL and 717 with follicular lymphoma. Anthracycline users were slightly younger (median age 64.03 vs 65.2 years (p-value 6 cycles, the cumulative risks were 4.01 %, 7.86% and 9.33% (fig 1). Compared to patients receiving non-anthracycline containing chemotherapy (reference), patients receiving anthracycline containing chemotherapy had a higher risk of developing HF during follow-up with adjusted hazard ratio (HR) of 3.73 (95% CI 1.38-10.09) for patients receiving 3-5 cycles, 4.38 (95% CI 1.83-10.48) for patients receiving 6 cycles, and 8.22 (95% CI 3.50-19.31) for patients receiving >6 cycles of anthracycline treatment. Conclusion: This present studyconfirms that inclusion of anthracyclines in a multi-agent chemotherapy regimen is responsible for the increased risk of HF observed after treatment for lymphoma and that the rate of HF is correlated to the number of treatment cycles. Patients treated without anthracyclines had a negligible risk of HF supporting the safety of these regimens in patients considered at substantial risk of cardiotoxicity. Download : Download high-res image (132KB) Download : Download full-size image Disclosures Jorgensen: Roche: Research Funding. Poulsen: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. El-Galaly: Roche: Other: Travel funding; Takeda: Other: Travel funding." @default.
• W2782372411 created "2018-01-12" @default.
• W2782372411 creator A5008802702 @default.
• W2782372411 creator A5018751853 @default.
• W2782372411 creator A5026722843 @default.
• W2782372411 creator A5030161973 @default.
• W2782372411 creator A5030813540 @default.
• W2782372411 creator A5037713780 @default.
• W2782372411 creator A5040068557 @default.
• W2782372411 creator A5041511205 @default.
• W2782372411 creator A5043782124 @default.
• W2782372411 creator A5064998022 @default.
• W2782372411 creator A5073812314 @default.
• W2782372411 creator A5087431344 @default.
• W2782372411 creator A5090246569 @default.
• W2782372411 date "2017-12-07" @default.
• W2782372411 modified "2023-10-10" @default.
• W2782372411 title "Lymphoma Patients Treated without Anthracyclines Have Negligible Risk of Cardiotoxicity: A Nationwide Cohort Study" @default.
• W2782372411 doi "https://doi.org/10.1182/blood.v130.suppl_1.2843.2843" @default.
• W2782372411 hasPublicationYear "2017" @default.
• W2782372411 type Work @default.
• W2782372411 sameAs 2782372411 @default.
• W2782372411 citedByCount "0" @default.
• W2782372411 crossrefType "journal-article" @default.
• W2782372411 hasAuthorship W2782372411A5008802702 @default.
• W2782372411 hasAuthorship W2782372411A5018751853 @default.
• W2782372411 hasAuthorship W2782372411A5026722843 @default.
• W2782372411 hasAuthorship W2782372411A5030161973 @default.
• W2782372411 hasAuthorship W2782372411A5030813540 @default.
• W2782372411 hasAuthorship W2782372411A5037713780 @default.
• W2782372411 hasAuthorship W2782372411A5040068557 @default.
• W2782372411 hasAuthorship W2782372411A5041511205 @default.
• W2782372411 hasAuthorship W2782372411A5043782124 @default.
• W2782372411 hasAuthorship W2782372411A5064998022 @default.
• W2782372411 hasAuthorship W2782372411A5073812314 @default.
• W2782372411 hasAuthorship W2782372411A5087431344 @default.
• W2782372411 hasAuthorship W2782372411A5090246569 @default.
• W2782372411 hasConcept C121608353 @default.
• W2782372411 hasConcept C126322002 @default.
• W2782372411 hasConcept C141071460 @default.
• W2782372411 hasConcept C143998085 @default.
• W2782372411 hasConcept C2776694085 @default.
• W2782372411 hasConcept C2776802502 @default.
• W2782372411 hasConcept C2778233292 @default.
• W2782372411 hasConcept C2778559949 @default.
• W2782372411 hasConcept C2908647359 @default.
• W2782372411 hasConcept C530470458 @default.
• W2782372411 hasConcept C71924100 @default.
• W2782372411 hasConcept C99454951 @default.
• W2782372411 hasConceptScore W2782372411C121608353 @default.
• W2782372411 hasConceptScore W2782372411C126322002 @default.
• W2782372411 hasConceptScore W2782372411C141071460 @default.
• W2782372411 hasConceptScore W2782372411C143998085 @default.
• W2782372411 hasConceptScore W2782372411C2776694085 @default.
• W2782372411 hasConceptScore W2782372411C2776802502 @default.
• W2782372411 hasConceptScore W2782372411C2778233292 @default.
• W2782372411 hasConceptScore W2782372411C2778559949 @default.
• W2782372411 hasConceptScore W2782372411C2908647359 @default.
• W2782372411 hasConceptScore W2782372411C530470458 @default.
• W2782372411 hasConceptScore W2782372411C71924100 @default.
• W2782372411 hasConceptScore W2782372411C99454951 @default.
• W2782372411 hasLocation W27823724111 @default.
• W2782372411 hasOpenAccess W2782372411 @default.
• W2782372411 hasPrimaryLocation W27823724111 @default.
• W2782372411 hasRelatedWork W1641876683 @default.
• W2782372411 hasRelatedWork W2028311823 @default.
• W2782372411 hasRelatedWork W2051449279 @default.
• W2782372411 hasRelatedWork W2138840241 @default.
• W2782372411 hasRelatedWork W2145453495 @default.
• W2782372411 hasRelatedWork W2226423794 @default.
• W2782372411 hasRelatedWork W2263741814 @default.
• W2782372411 hasRelatedWork W2521619398 @default.
• W2782372411 hasRelatedWork W2529027599 @default.
• W2782372411 hasRelatedWork W2534379449 @default.
• W2782372411 hasRelatedWork W2557195356 @default.
• W2782372411 hasRelatedWork W2570202202 @default.
• W2782372411 hasRelatedWork W2576377696 @default.
• W2782372411 hasRelatedWork W2586617225 @default.
• W2782372411 hasRelatedWork W2591810753 @default.
• W2782372411 hasRelatedWork W2900113449 @default.
• W2782372411 hasRelatedWork W2901183349 @default.
• W2782372411 hasRelatedWork W3031337279 @default.
• W2782372411 hasRelatedWork W3103930432 @default.
• W2782372411 hasRelatedWork W3133975016 @default.
• W2782372411 hasVolume "130" @default.
• W2782372411 isParatext "false" @default.
• W2782372411 isRetracted "false" @default.
• W2782372411 magId "2782372411" @default.
• W2782372411 workType "article" @default.